Drug intelligence / Profile preview

JO-4

Development stage: Unknown
Lead developer: Yeda Research & Development
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

JO-4 is a recombinant protein drug candidate designed to transiently open intercellular junctions in epithelial tissues by binding and modulating desmoglein 2. Its mechanism of action is to facilitate the access of co-administered anti-cancer agents, notably monoclonal antibodies or chemotherapeutics, into solid tumors by increasing tissue permeability. JO-4 is under investigation as an adjunct to cancer therapy to improve drug delivery, with preclinical and early-phase clinical studies showing promise for enhanced efficacy of biologics and chemotherapy in solid tumors.

Other names: JO-4JO4JO 4

Targets

DSG2 (Desmoglein-2)

Beyond the preview

Go deeper on JO-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JO-4.

Explore the full profile